Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...

In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance ...

The health of the thymus - a key part of the body's immune system - is associated with cancer patients' outcomes to immune checkpoint inhibitor treatment, according to a ground-breaking international ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Panelists discuss how the IMscin001 trial findings established subcutaneous atezolizumab noninferiority with comparable efficacy and safety to intravenous (IV) formulation while highlighting ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Primary results from the Phase III evERA Breast Cancer study, the first positive head-to-head Phase III trial investigating an all-oral selective estrogen receptor (ER) degrader-containing regimen ...

MIT and Harvard scientists have designed an advanced type of immune cell called a CAR-NK cell that can destroy cancer while ...

B96 to be featured in Presidential Symposium, underscoring the impact of KEYTRUDA® (pembrolizumab) in certain bladder and ovarian cancersData from multiple investigational medicines from Merck’s ...

Researchers have now come up with a new way to engineer CAR-NK cells that makes them much less likely to be rejected by the ...

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to ...